Navigation Links
Genesis Biopharma Conference Call and Webcast Reminder

LOS ANGELES, June 28, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, is holding a conference call with the investment community tomorrow, Wednesday, June 29, 2011 at Noon Eastern (9:00 a.m. Pacific).  The Company's Chairman and Chief Executive Officer, Anthony J. Cataldo, will provide an update on the business, and discuss the clinical and commercial development plans for the Company's new autologous cell therapy product candidate, Contego™, for the treatment of Stage IV metastatic melanoma.  There will also be a question and answer session following the presentation.

Individuals interested in listening to the conference call may do so by dialing 888-634-9408 for domestic callers, or 706-679-0879 for international callers, or from the webcast on the investor relations section of the Company's Web site at  A slide presentation will accompany the call and webcast, and will be available on the Company website.

A telephone replay will be available through July 1, 2011 by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering the Conference ID #: 78126182.  The webcast will be available on the Company's Web site for 60 days following the completion of the call.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit

Forward-Looking Statements

The foregoing announcement contains forward-looking statements that can be identified by such terminology as "expects", "hopes", "potential", "suggests", "bodes", "may", "should", "could", or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general.  Forward-looking statements speak only as of the date they are made.  The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
2. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
3. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
4. ThermoGenesis Announces China Customer Implements Cord Blood Products
5. Tissue Genesis Begins FDA-Approved Clinical Trial
6. CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
7. Organogenesis, Life Sciences Center Break Ground on Worlds Largest Automated Living Cell Manufacturing Plant
8. Announcing ValGenesis On-Demand SaaS Solution
9. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
10. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
11. Genesis Biopharma Announces Plans to Develop Active Immunotherapy Platform
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/17/2015)... PARIS , November 17, 2015 ... November 2015.   --> Paris from ... --> DERMALOG, the biometrics innovation leader, has invented the ... and fingerprints on the same scanning surface. Until now two ... fingerprints. Now one scanner can capture both on the same ...
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
Breaking Biology News(10 mins):